PureTech Health PLC Annual Capital Markets Meeting
May 09 2017 - 2:00AM
RNS Non-Regulatory
TIDMPRTC
PureTech Health PLC
09 May 2017
PureTech Health Annual Capital Markets Meeting, London
Annual Capital Markets Meeting
PureTech Health plc ("PureTech Health" or the "Company", LSE:
PRTC), an advanced, clinical-stage biopharmaceutical company, is
today holding its second annual Capital Markets Meeting in London.
The Company will provide insight into its near-term
commercialisation and monetisation strategy as well as insights
into its growing research and development pipeline.
The meeting will take place in London from 13.00-17.00 BST and
will feature PureTech Health presenters including members of the
Company's Board of Directors and key scientific advisors.
Speaker Topic
----------------------------------- ------------------------------------
Chris Viehbacher Welcome: Perspectives
Independent Non-Executive on PureTech Health's
Director, PureTech Health; unique place in biopharma
Managing Partner at Gurnet ecosystem
Point Capital and Former
CEO of Sanofi
----------------------------------- ------------------------------------
Daphne Zohar Building a modern biopharma
Co-Founder & Chief Executive company
Officer, PureTech Health
----------------------------------- ------------------------------------
Near-Term Catalysts
-------------------------------------------------------------------------
LeRoux Jooste Akili Interactive: Imagine
Chief Commercial Officer, what medicine can be
Akili Interactive; Former
CCO/SVP of Business Development
at Ocata (Astellas)
----------------------------------- ------------------------------------
Eddie Martucci, Ph.D.
Vice President, PureTech
Health; Co-Founder and Chief
Executive Officer, Akili
Interactive
----------------------------------- ------------------------------------
Raju Kucherlapati, Ph.D. Transitioning from a
Independent Non-Executive clinical to commercial-stage
Director and Scientific Advisory biopharma company
Board Member, PureTech Health;
Co-founder of Millennium
Pharmaceuticals and Abgenix
----------------------------------- ------------------------------------
Eric Elenko, Ph.D. Gelesis: Targeting the
Chief of Research and Strategy, genesis of chronic disease
PureTech Health
----------------------------------- ------------------------------------
Follica: Resetting the
clock on skin biology
----------------------------------- ------------------------------------
John LaMattina, Ph.D. Developing new classes
Independent Non-Executive of medicine
Director, PureTech Health;
Former President of Global
Research and Development
at Pfizer
----------------------------------- ------------------------------------
Bernat Olle, Ph.D. Vedanta Biosciences:
Vice President, PureTech Microbiome-derived immunotherapies
Health; Co-Founder and Chief
Executive Officer, Vedanta
Biosciences
----------------------------------- ------------------------------------
Partnering with Big Pharma to Advance Important
New Medicines
-------------------------------------------------------------------------
Bennett Shapiro, M.D. Partnering with big
Co-Founder & Non-Executive pharma to advance important
Director, PureTech Health; new medicines
Former Executive Vice President
of Research at Merck
----------------------------------- ------------------------------------
Andrew Miller, Ph.D. Karuna Pharmaceuticals:
Vice President, PureTech Treating cognition and
Health; Co-Founder and Chief psychosis associated
Executive Officer, Karuna with neurological disease
Pharmaceuticals
----------------------------------- ------------------------------------
Chen Schor resTORbio: Aging and
Senior Executive, PureTech the immune system
Health; Co-Founder and Chief
Executive Officer, resTORbio
----------------------------------- ------------------------------------
A Growing Immunology Pipeline and the Next Wave
of Innovation
-------------------------------------------------------------------------
Joe Bolen, Ph.D. The adaptive human systems
Chief Scientific Officer, and a growing immunology
PureTech Health; Former President pipeline
and CSO of Moderna and former
CSO of Millennium (Takeda)
----------------------------------- ------------------------------------
Aleks Radovic-Moreno, Ph.D. Commense: Developing
Senior Associate, PureTech microbiome-derived interventions
Health; Co-Founder of Commense, for maternal and paediatric
Alivio, and Vor; Formerly health
MIT
Alivio: Treating chronic
and acute inflammatory
disorders
Vor: Developing next-generation
engineered cell therapies
in oncology
----------------------------------- ------------------------------------
Aleks Filipovic, M.D., Ph.D. Nybo: Developing monoclonal
Therapeutic Lead for Oncology, antibodies to target
PureTech Health; Co-Founder pancreatic cancer and
of Nybo; Formerly Imperial other solid tumours
College
----------------------------------- ------------------------------------
Grace Teo, Ph.D. Concept stage programmes:
Associate, PureTech Health; The next wave of innovation
Co-Founder of Nybo; Formerly
MIT
----------------------------------- ------------------------------------
David Steinberg Translating innovation
Chief Innovation Officer, into medicine
PureTech Health
----------------------------------- ------------------------------------
Atul Pande, M.D.
Chief Medical Officer, PureTech
Health;
Former Senior Vice President
and Head of Neuroscience
at GSK
----------------------------------- ------------------------------------
Bharatt Chowrira, Ph.D., Unlocking value
J.D.
President and Chief of Business
and Strategy, PureTech Health;
Former President of Synlogic
and COO of Auspex (Teva)
----------------------------------- ------------------------------------
Marjorie Scardino Closing remarks
Senior Independent Director,
PureTech Health;
Former CEO of Pearson plc
and The Economist
----------------------------------- ------------------------------------
If you would like to attend the event, please contact
PureTech.Event@fticonsulting.com
About PureTech Health
PureTech Health (PureTech Health plc, PRTC.L) is an advanced,
clinical-stage biopharmaceutical company developing novel medicines
that modulate the adaptive human systems. PureTech's therapies
target the dysfunctions in the immune, nervous, and
gastro-intestinal systems by addressing the underlying
pathophysiology of disease from a systems perspective rather than
through a single receptor or pathway. The Company is advancing a
rich pipeline that includes multiple human proof-of-concept studies
and pivotal or registration studies expected to read out over the
next 12-18 months. PureTech Health's growing research and
development pipeline has been developed in collaboration with some
of the world's leading scientific experts, who along with
PureTech's experienced team and a stellar Board identify, analyse
and advance very selectively the opportunities the Company believes
hold the most promise for patients. This experienced and engaged
team places PureTech Health at the forefront of ground-breaking
science and technological innovation and leads the Company between
and beyond existing disciplines. For more information, visit
www.puretechhealth.com or connect with us on Twitter
@puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
For further information:
PureTech Health FTI Consulting
Allison Mead Ben Atwell, Matthew
+1 617 651 3156 Cole, Rob Winder
amead@puretechhealth.com +44 (0) 20 3727 1000
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAASPEFFXEAF
(END) Dow Jones Newswires
May 09, 2017 02:00 ET (06:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024
